Skip to main content
Premium Trial:

Request an Annual Quote

Mary Schramke, Patrice Milos, Chip Leveille, William Cotter, Mark Solakian, Victor Velculescu, David Gelfand

Premium
Mary Schramke has left her post as vice president of marketing at 454 Life Sciences, In Sequence has learned. She left the company at the end of May. Brendon Hill, sales manager at 454, confirmed that Schramke had left the firm, but was unable to provide further details of her departure.
 
Schramke joined 454 last fall from Solexa, where she was vice president and general manager of its genomic services division. She had been head of product development and interim chief executive officer of Lynx Therapeutics before it acquired Solexa in late 2005.
 

 
Patrice Milos has joined Helicos BioSciences as chief scientific officer. Milos joins the firm from Pfizer Global Research and Development, where she most recently held the position of executive director. Milos joined Pfizer in 1993 and held various research positions focusing on pharmacogenomics and molecular sciences.
 
Milos is a member of the National Advisory Council for Human Genome Research. She holds a Master's and PhD degree from Rensselaer Polytechnic Institute and a BA from the College of Saint Rose in Albany.
 
Helicos has also disclosed on its website that Chip Leveille has recently joined the company as vice president of sales and marketing, William Cotter has been hired as vice president of operations, and Mark Solakian has joined as vice president, corporate counsel, and secretary.
 
Leveille was most recently vice president at Affymetrix, where he managed the company’s pharmaceutical business unit, core technologies group, and corporate marketing for the systems business unit. Prior to Affy, Leveille spent 12 years at Zymark in various sales and business development roles.
 
Cotter, prior to joining Helicos, was the vice president of operations for Closure Medical, a manufacturer of synthetic surgical adhesives and sealants that was acquired by Johnson & Johnson in 2005. Before that, he worked for Sanofi Diagnostic Pasteur, Genetic Systems, and Advanced Technology Laboratories.
 
Solakian was most recently vice president and chief corporate counsel for Affymetrix. Prior to that, he was an attorney at Goodwin Procter.
 
In addition, Victor Velculescu joined the company’s scientific advisory board “a few months ago,” according to a Helicos spokeswoman. Velculescu, director of cancer genetics at the LudwigCenter and associate professor of oncology at the Johns Hopkins University Kimmel Cancer Center, is known for developing the serial analysis of gene expression method for global gene expression profiling, among other genomic technology innovations.
 

 
David Gelfand has joined WaferGen Bio-systems as chief scientific officer. Gelfand helped develop PCR at Cetus in the 1980s. He also served as vice president of discovery research and director for the program in core research at Roche Molecular Systems. In 1990, Gelfand was the recipient of the US Distinguished Inventor Award for Taq DNA Polymerase.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.